{
  "id": 8885070,
  "title": "Syncona jumps 6% after Beacon gene therapy trial success",
  "url": "https://urgent.news/2026/09/21/syncona-jumps-6-after-beacon-gene-therapy-trial-success",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-21T09:00:41.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/stock-market-news/syncona-jumps-6-after-beacon-gene-therapy-trial-success-4908450"
  },
  "original_language": "en",
  "account": null,
  "summary": "Syncona's shares surged by approximately 6% on Monday following Beacon Therapeutics' announcement that its gene therapy for a rare inherited eye disease, X-linked retinitis pigmentosa (XLRP), met its primary endpoint in a late-stage trial. The VISTA trial, which tested laruparetigene zovaparvovec (laru-zova), involved 85 male patients aged 12 to 48 with XLRP caused by RPGR gene mutations. At 12 months, the trial showed that 31% of patients receiving the high dose and 24.1% of those receiving the low dose improved by at least 15 letters in low-luminance visual acuity, compared to none in the untreated control group. Beacon plans to initiate discussions with global regulators and commence a rolling Biologics License Application later this year.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Endpoints News",
        "title": "Beacon says gene therapy succeeds in key trial of rare eye disease XLRP",
        "url": "https://urgent.news/2026/09/21/beacon-says-gene-therapy-succeeds-in-key-trial-of-rare-eye-disease",
        "published": "2026-09-21T06:00:58.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}